Philippe Camus, M.D.
Dijon, France
Daunorubicin, doxorubicin, epirubicin, idarubicin
Left ventricular dysfunction/failure
Evidence level
possible
Late left ventricular dysfunction/failure
definite
Cardiomyopathy (acute, subacute, chronic)
strong
‘Cardiotoxicity’
Pulmonary edema, cardiogenic
low